Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Formulated Methylene Blue for Advanced Squamous Cell Carcinoma
NCT07311057Phase 3Enrolling by invitation
- Start
- Dec 2025
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of methylene blue in squamous cell carcinoma (SCC). Primary endpoint: Rate of Wound Healing and Tumor Regression at 12 weeks. Started Dec 2025; status: enrolling by invitation.
02
Drugs
methylene blue
03
Conditions
squamous cell carcinoma (SCC)
Beyond the preview
Go deeper on NCT07311057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07311057.